CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Etomidate Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2022-10-05. Latest FDA row update: 2026-10-05.
FDA lists 18 package records, with companies: Armas Pharmaceuticals Inc., Caplin Steriles, Ltd., Civica, Inc., Eugia US LLC, Fosun Pharma USA Inc, Fresenius Kabi USA, LLC, Gland Pharma Limited, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., Hospira, Inc., Hospira, Inc., a Pfizer Company, Mylan Institutional LLC, Mylan Institutional, a Viatris Company. Package NDCs: 0143-9310-10, 0143-9311-10, 0143-9506-10, 0143-9507-10, 0409-6695-01, 0409-6695-02, 55150-221-10, 55150-222-20, 65219-445-10, 65219-447-20, 67457-902-10, 67457-903-20, 72266-146-10, 72266-147-10, 72485-508-10, 72485-509-10, 72572-160-10, 72572-161-10.
FDA shortage reason: Demand increase for the drug; Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Caplin Steriles, Ltd. | 72485-508-10 | Etomidate, Injection, 2 mg/mL (NDC 72485-508-10) | Available | 2026-06-16 |
| Caplin Steriles, Ltd. | 72485-509-10 | Etomidate, Injection, 2 mg/mL (NDC 72485-509-10) | Available | 2026-06-16 |
| Caplin Steriles, Ltd. | 65219-445-10 | Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10) | Available | 2026-06-16 |
| Caplin Steriles, Ltd. | 65219-447-20 | Etomidate, Injection, 2mg/mL (NDC 65219-447-20) | Available | 2026-06-16 |
| Eugia US LLC | 55150-221-10 | Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10) | Unavailable | 2026-10-02 |
| Eugia US LLC | 55150-222-20 | Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20) | Unavailable | 2026-10-02 |
| Gland Pharma Limited | 72266-146-10 | Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10) | Available | 2026-07-22 |
| Gland Pharma Limited | 72266-147-10 | Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10) | Available | 2026-07-22 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9310-10 | Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9311-10 | Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9506-10 | Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9507-10 | Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 72572-160-10 | Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 72572-161-10 | Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10) | Available | 2026-09-18 |
| Hospira, Inc., a Pfizer Company | 0409-6695-01 | Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-6695-02 | Amidate, Injection, 2 mg/mL (NDC 0409-6695-02) | Unavailable | 2026-08-24 |
| Mylan Institutional, a Viatris Company | 67457-902-10 | Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10) | Available | 2026-09-17 |
| Mylan Institutional, a Viatris Company | 67457-903-20 | Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20) | Available | 2026-10-05 |
Source facts
Grouped generic ingredient: Etomidate Injection · 18 package records
Therapeutic categories: Anesthesia
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.